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Blood pressure, left ventricular hypertrophy and long-term prog-
nosis in hemodialysis patients. Cardiovascular events are the
main cause of death in patients with chronic renal failure who are
treated with hemodialysis. Hypertension is frequent among dial-
ysis patients and may be a major cause of mortality, although
epidemiological studies are controversial in this regard. This
disparity in results may be the consequence of an inadequate
definition of hypertension in dialysis patients as well as the
interaction with hypertension with other risk factors such as
malnutrition or left ventricular hypertrophy (LVH), which are
strong predictors of death. Although the goal of blood pressure in
dialysis has not been established yet, it seems that predialysis
blood pressure levels lower than 150/90 mm Hg must be achieved
for patients to avoid complications. LVH is very frequent among
dialysis patients and starts early in the progression of chronic
renal failure. Hypertension is the main cause for its development,
but other potentially reversible factors such as anemia, volume
overload, secondary hyperparathyroidism, dose of dialysis or
malnutrition may also be implicated. Hence, an adequate man-
agement of patients on hemodialysis must include the strict
control of blood pressure, preferably with angiotensin converting
enzyme (ACE) inhibitors, together with those early measures in
order to avoid the development of the other causes of LVH or to
treat them when they already exist.
Patients on chronic hemodialysis have an age-adjusted
death rate 3.5 times higher than the general population [1].
This poor prognosis can be explained by their high comor-
bidity [2, 3]. Cardiovascular events are the main cause of
death, 54% among hemodialysis patients in USA [2] and
47% in Europe (Valderra´bano et al, this issue). Arterio-
sclerosis is more frequent, severe and appears early in these
patients [4]. Hypertension has been shown to be a strong
predictor of mortality in general population [5]. It has
generally been accepted that the blood pressure (BP)
linked to a low cardiovascular risk is that lower than 120/80
mm Hg [6] and in this sense, about 80% of patients on
hemodialysis have a BP higher than this level [7]. All these
data suggest that hypertension would be a major cause of
mortality in dialysis patients, however, the results of epide-
miological studies are controversial.
Some published studies show a direct relationship be-
tween both systolic and diastolic predialysis BP and the
mortality rate [8–11]. Antihypertensive therapy improves
the one-year mortality rate irrespective of the level of BP
control [12]. Sometimes it is necessary to look for the
association of several cardiovascular factors, such as hyper-
cholesterolemia, systolic BP, and cigarette smoking, to find
a relationship with the mortality rate [13]. Moreover,
hypertension has been implicated in the development of
left ventricular hypertrophy (LVH) [3], arteriosclerosis [4]
and ischemic cardiomyopathy [14]. In contrast, other au-
thors show that high BP is not an independent risk factor of
death [15–18], even among diabetic patients [19]. Greaves
and Sharpe found an inverse relationship between predi-
alysis diastolic BP at the beginning of hemodialysis therapy
and the gross mortality rate [1]. These authors also describe
that malnourished patients often have a low diastolic BP,
suggesting that nutritional factors would be a strong pre-
dictor of mortality in dialysis patients [1, 20]. Moreover, an
inverse relationship between BP and mortality rate has also
been described to be a result of congestive heart failure [3].
Only 6.6% of long-term surviving patients on hemodialysis
have a systolic BP lower than 110 mm Hg [21], and a
systolic dysfunction must be suspected in these cases.
In our experience, neither systolic or diastolic BP are
independent risk factors of death in hemodialysis patients.
A study of survival cofactors in a cohort of 193 patients with
more than six months on hemodialysis was performed. The
clinical and demographic characteristics of the patient
cohort at six months of patient entry on hemodialysis are
shown in Table 1. Patients were evaluated at six months
from the onset of hemodialysis and the results were related
with the outcome data after a mean period of 81 6 65
months. At the end of the study, 82 patients had died, 11
were lost to follow-up, and 100 were alive on treatment.
Seventy-three percent of them were on hemodialysis with
low permeability and compatible membranes, and the
remaining patients used high performance membranes.
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Causes of death were: cardiovascular 27%, infectious dis-
ease 24%, dementia and cerebrovascular events 16%,
unknown etiology in 12%, and malignancies 11%. In uni-
variate analysis comparing the variables between death and
survival patients, age, serum creatinine and albumin, pro-
tein catabolism rate (PCR), hemoglobin, arm mean muscle
circumference (AMMC) and postdialysis systolic BP were
significantly different between both groups at six months
after starting dialysis. No differences were found in systolic
and diastolic predialysis BP, postdialysis diastolic BP, left
ventricular mass index (LVMI), Kt/V, total CO2, PTH,
serum cholesterol and triglycerides, high density lipopro-
tein (HDL) and low density lipoprotein (LDL) cholesterol
nor body mass index. Using Cox regression modeling, age
alone, low serum creatinine and diabetes mellitus were
independent risk factors of death.
The disparity in the results from the different studies
may depend upon: (a) statistical analyses that do not clearly
define the outcome risk factors for hemodialysis [22]; (b)
interaction of hypertension with other risk factors such as
malnutrition; (c) the controversy over an established ade-
quate definition of hypertension in dialysis patients; and (d)
the strong relationship between cardiovascular mortality
and LVH, which is very influenced by factors other than
hypertension. The last two aspects are reviewed in the next
sections.
WHAT FACTORS INFLUENCE PATIENT BLOOD
PRESSUE DURING HEMODIALYSIS?
When must the patient be considered hypertensive?
Hemodialysis sessions produce cyclic changes in sodium
and water content that are related to BP. We studied the
mean BP before and after three hemodialysis sessions from
one week, and the results are compared with basal BP
values obtained from the hospital during the three next
days without hemodialysis (Table 2). Both predialysis and
postdialysis BP had a strong relationship with basal BP,
suggesting that BP obtained from a patient on hemodialysis
could be an estimate of the basal BP, although the levels
are different. Predialysis BP overestimated basal BP while
postdialysis BP underestimated it, although the latter was
closer to the basal BP value. The decrease of BP during
hemodialysis was lesser in hypertensive patients. Postdialy-
sis BP and the mean between pre- and post-hemodialysis
BP values were more closely correlated with basal inter-
dialysis BP. Some studies using 24- to 48-hour BP monitor-
ing confirm these concepts [23]. LVH is better correlated
with predialysis systolic BP [23] and nocturnal systolic BP.
The loss of a BP circadian rhythm is frequently found in
these patients, and more accentuated in hypertensive pa-
tients and those with volume overload [24, 25].
Blood pressure in hemodialysis patients depends mainly
on the hydration state [26–28]. In our experience, BP does
not change significantly throughout the first four years on
hemodialysis (Table 3). There is no relationship between
the interdialysis weight gain and the predialysis BP. Hyper-
tensive patients do not seem to have a higher weight gain,
although predialysis BP in each patient does have a good
correlation with the weight gain. After the week’s end, BP
tends to be higher and is related with a higher weight gain.
An increase of BP at the end of a hemodialysis session was
found in 7% of all the sessions during a three month period
in 40 patients. It could be related to a sympathetic reaction
Table 1. Characteristics of the study population
Age years 60 6 15 (19–85)
Male/female % 60/40








Predialysis blood pressure mm Hg 144/79 6 21/12.5
Postdialysis blood pressure mm Hg 125/71 6 23/13
Patients with antihypertensive therapy % 32
LVH in echocardiography (168 pat) % 88
Evaluated parameters were
PCR g/kg/day 1.02 6 0.29
Kt/V (Daugirdas II) 1.09 6 0.25
Relationship between Kt/V and PCR
(N 5 192)
r 5 0.424, P , 0.001;
PCR 5 0.475 1
0.506*Kt/V
Predialysis creatinine mol/liter 844 6 255
Albumin g/liter 41 6 6
Total CO2 mmol/liter 22.3 6 3.6
Serum iPTH pg/ml 319 6 334
Hematocrit % 30.3 6 5.1
Hemoglobin g/dl 10.1 (52% with
rHuEPO)
Cholesterol mmol/liter 5.34 6 1.42
Triglycerides g/liter 1.55 6 1.18
HDL cholesterol mmol/liter 0.39 6 0.13
LDL cholesterol mmol/liter 1.35 6 0.43
Body mass index kg/m2 22.3 6 4.4
Arm mean muscle circumference cm 22 6 4
This is from a prospective cohort study of 193 patients who survived
more than 6 months on hemodialysis (HD). Baseline evaluation 6 months
after HD onset and posterior follow-up is 81 6 65 months. Blood pressure
pre- and post-HD average of 12 hemodialysis sessions at sixth months
after the onset of HD. LVH is left ventricular hypertrophy. Values are
expressed as mean 6 SD.
Table 2. Blood pressure (BP) pre- and post-hemodialysis (HD) and the
next day (NDBP), in 40 hemodialysis patients
Pre-HD BP Post-HD BP NDBP
mm Hg
Systolic BP 140 6 21 120 6 20 127 6 20
Diastolic BP 79 6 13 69 6 11 73 6 11
Data are the mean BP of the three HD sessions and at the next day in
a week.
Correlations between: preHD systolic BP and systolic NDBP are r 5
0.77, N 5 40; PreHD diastolic BP and diastolic NDBP are r 5 0.81, N 5
40; Post-HD systolic BP and systolic NDBP are r 5 0.89, N 5 40;
post-HD diastolic BP and diastolic NDBP, r 5 0.86, N 5 40; P , 0.01.
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in response either to an exaggerated ultrafiltration or to the
antihypertensive agent’s clearance by dialysis.
With all the previous arguments, it is difficult to establish
which BP measurement has the higher prognostic value. No
matter which method of measurement is used, however,
several measurements of BP must be taken, and when it is
higher than 150/90 mm Hg, the diagnosis of hypertension
must be considered in that patient.
The prevalence of hypertension in hemodialysis patients
is very different in the literature, ranging from 2 to 58% [9,
24]. In Tassim, France, with its longer duration of hemo-
dialysis sessions and a Kt/V . 1.5 (mean 1.7), the preva-
lence of hypertensive patients is around 2% [8]. In our
study, 28% of the patients had predialysis systolic BP
higher than 150 mm Hg and 12% had diastolic BP higher
than 90 mm Hg. Postdialysis measurements showed that
10% of the patients had systolic hypertension and only 1%
had diastolic hypertension. Cheigh et al found that 58% of
patients had systolic and 39% diastolic hypertension. These
authors suggest that hypertension is not adequately con-
trolled in hemodialysis patients because it is not an easy
task [24]. Differences in the prevalence of hypertension
found among the various studies are likely due to patient
characteristics such as race, social and economic status, and
etiology of CRF, but the characteristics of hemodialysis and
an inadequate sodium balance are highly implicated.
LEFT VENTRICULAR HYPERTROPHY IN
HEMODIALYSIS PATIENTS
Left ventricular hypertrophy (LVH) is a compensatory
response of the left ventricle to increase hemodynamic
load. This structural abnormality includes two patterns:
concentric LVH, where the cause is a cardiac afterload due
to hypertension, which induces a lateral expansion of
cadiomyocytes as well as proliferation of fibroblasts. The
second pattern is the excentric LVH, a response to cardiac
overload from anemia, arteriovenous fistula or volume
overload, which results in an elongation of the myocyte.
LVH is also accompanied by a reduced capillarization with
a decrease in O2 diffusion [29, 30].
The prevalence of LVH among hemodialysis patients is
very high [31]. It can appear very early in the progression of
CRF and may be present at the start of dialysis treatment
[32, 33]; LVH is an independent risk factor of death in
patients on dialysis [32, 34]. Actually, about one-half of the
deaths of dialysis patients are due to cardiovascular events
[2], which strongly implicates LVH as a primary risk factor
[17].
Some direct consequences of LVH include poor toler-
ance to ultrafiltration on hemodialysis, congestive hearth
failure, arrhythmia, angina pectoris and myocardial infarc-
tion, all of which may contribute to a high cardiovascular
mortality [17, 29, 35–37].
RISK FACTORS FOR LEFT VENTRICULAR
HYPERTROPHY
Hypertension is the main cause for the development of
LVH [3, 32, 38–40], but other potentially reversible factors
such as anemia, volume overload, secondary hyperparathy-
roidism, uremia, dose of dialysis, and malnutrition may
have an important role in its pathogenesis [41].
Anemia
Typically, anemia in CRF patients on dialysis is accom-
panied by an hyperdynamic state with an increase in cardiac
output and LV volume overload, which are directly related
with the development of LVH [42, 43]. This process may
induce a loss of myocardial contractility and contribute to
LV dysfunction. Moreover, anemia is an independent risk
factor for cardiac morbidity and mortality in ESRD pa-
tients [39, 44].
Partial correction of anemia with recombinant human
erythropoietin (rhEPO) is associated with a decrease in
LVH, especially due to a reduction in LV end diastolic
diameter that is independent of age [45, 46]. Radermacher
and Koch reviewed fifteen published studies, including
patients who were treated with rhEPO during a mean time
of 45 weeks. A partial correction of anemia to a steady-
state hematocrit of 32.9% was obtained, which resulted in
approximately an 18% decline in the LV mass index [47].
However, the improvement of LV mass did not reach
Table 3. Blood pressure (BP) and interdialytic weight gain (IGW) in 40








4th T–first year 141 6 21/79 6 14 60 6 10.1 1863 6 965a
4th T–2nd year 143 6 23/80 6 13 60 6 10.7 2159 6 800
4th T–3rd year 144 6 22/80 6 12 60.5 6 11.1 2185 6 847
4th T–4th year 144 6 24/79 6 12 60.9 6 11.4 2064 6 796
Data are the mean of BP and interdialytic weight gain of all sessions
during last trimester (T). No significant relationship was found between
BP and IWG in the group, but in each patient.
a P , 0.05 vs. 2nd, 3rd and 4th year after beginning HD
Table 4. Changes in left ventricular dimensions and function after
dialysis (N 5 12)
LV before LV after
Pdialysis
LVEDD mm 49.4 6 8.3 42.1 6 9.0 , 0.05
IVST mm 11.4 6 2.4 11.6 6 2.1 NS
LVPWT mm 11.9 6 2.3 11.9 6 1.1 NS
LVMI g/m2 134.2 6 41.0 105.9 6 37.5 , 0.05
E WAVE cm/sec 95.6 6 31.4 70.5 6 22.4 , 0.05
A WAVE cm/sec 86.1 6 20.0 78.9 6 19.4 NS
% Shortening 33.7 6 14.9 35.9 6 14.6 NS
Ejection fraction 45.9 6 16.4 48.7 6 15.5 NS
Mean weight loss was 2.1 6 0.6 kg. Abbreviations are: LVEDD, left
ventricular end diastolic diameter; IVST, interventricular septum thick-
ness; LVPWT, left ventricular posterior wall thickness; LVMI, left ven-
tricular mass index.
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normal values, suggesting either that this event was a
multifactorial etiology where anemia was only a partial
responsible factor, or that the hematocrit obtained was not
sufficient for a complete normalization of LVH.
Beneficial effects of rhEPO therapy on LV mass may be
counteracted by an increase in systemic vascular resistance,
which may produce hypertension and cardiac overload [48,
49]. Withdrawing rhEPO therapy is followed by an in-
creased in LV mass index and cardiac output with a
decrease in peripheral vascular resistance [50], which con-
firms the role of rhEPO on the cardiac hemodynamics.
Volume overload
Salt and water retention is not only the major factor
implicated in dialysis hypertension [28, 51, 52], but it may
have a direct hemodynamic effect of increasing the cardiac
preload. Echocardiographic findings show that interdialysis
weight gain is accompanied by an increase in LVMI, mainly
due to a rise in LV end diastolic diameter, which may have
a long term effect on the development of LVH. Table 4
shows the changes in LV dimensions and function in 12
patients studied before and after a midweek hemodialysis
session, with a mean weight loss of 2.1 kilograms.
Secondary hyperparathyroidism
Hyperparathyroidism (HPTH) is a common complica-
tion of CRF patients. It can be present very early in the
decline of renal function, but mainly is found when an
adequate control of calcium-phosphorous metabolism is
not performed. In experimental models, it has been shown
that parathyroid hormone (PTH) leads to cardiac fibrosis
[53, 54] throughout the cardiac receptors for PTH in
cardiac fibroblasts and myocardiocytes [55]. The relation-
ship between HPTH and cardiac dysfunction is controver-
sial [40, 56–58], but HPTH produces an increase in cyto-
solic free calcium that may result in chronotropic and
inotropic effects on the myocardial cells [59, 60]. Together
with other factors these changes may contribute to cardiac
hyperthrophy [40, 57, 61]. In addition, a calcium phosphate
deposition on the coronary microcirculation and athero-
sclerosis induced possibly by HPTH can predispose the
patient to ischemic cardiomyopathy [62].
Until now, it has not been shown that a decline in serum
levels of PTH after calcitriol treatment would be associated
with an improvement of LVH. We did not find a significant
relationship between PTH levels and LVMI in a group of
37 patients on hemodialysis. However, severe HPTH may
play a certain role in the genesis of LVH. In this regard, we
studied 12 patients on hemodialysis before and six months
after total parathyroidectomy, using echocardiography.
LVMI decreased significantly, which overall was due to a
lower LV end diastolic diameter, but we also found an
increase in hematocrit. Hence, these findings could not
explain the true influence of the decrease in PTH levels per
se on the cardiac hypertrophy, because the beneficial effect
could partially be explained by the improvement of anemia
[63].
Dialysis dose
There is some direct evidence that the dialysis dose is
inversely related with both gross and cardiovascular mor-
tality in hemodialysis patients [64–66]m and directly re-
lated with an improvement in cardiac structure abnormal-
ities and dysfunction [67]. We studied 37 normotensive
patients who had no previous ischemic heart disease,
valvular disease or specific heart treatment. Patients were
classified into two groups according to a Kt/V higher or
lower than 1.1. We found a significant correlation be-
tween LV end diastolic diameter and Kt/V. A higher
prevalence of LV dilation was also found in the group
Fig. 1. Relationship between left ventricular
mass index (LVMI) and Kt/V (Daugirdas 2) in
37 patients on hemodialysis (r 5 20.39; P 5
0.01)
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with the lower dose (36% vs 5%, P , 0.005). Moreover,
Kt/V correlated to LVMI (Fig. 1). There were no
differences in systolic function in the two groups, while
diastolic dysfunction was more frequently found in the
group with Kt/V , 1.1 (81.2% vs 38.0%, P , 0.01). The
logistical regression model showed a significant associa-
tion between lower dialysis dose and diastolic dysfunc-
tion (OR 5 6.36; P 5 0.02) independently from LVH.
Thus, the dialysis dose must be considered to be a uremic
cardiomyopathy-related factor in hemodialysis patients
[68].
Malnutrition
Hypoalbuminemia has been independently related to
both relative risk of death and LV dilation in dialysis
patients [16, 20, 32, 38, 64, 69]. It also predisposes the
patient to the development of both de novo congestive
heart failure and de novo ischemic heart disease [37, 70].
This association may partially explain the adverse effect
that malnutrition has on the survival, although the closed
mechanism is not yet clarified.
MANAGEMENT OF ARTERIAL HYPERTENSION AND
LEFT VENTRICULAR HYPERTROPHY
The management of cardiovascular problems of end-
stage renal disease (ESRD) patients must be attended to
carefully to prevent all of the risk factors and manifesta-
tions. Hypertension must be controlled in patients on
hemodialysis to avoid an impairment of tolerance to dial-
ysis and the risk of malnutrition. BP control needs to be
associated with the treatment as well as to other factors
implicated in the development of LVH, such as hyperpara-
thyroidism, hypoalbuminemia and anemia. These measure-
ments must be started early in the treatment and progres-
sion of CRF, to avoid the reported high prevalence of
cardiovascular manifestations at the onset of dialytic ther-
apy [32].
When both an adequate dose of hemodialysis, with a
Kt/V higher than 1.2, and a sodium and fluid restriction are
obtained, the number of hypertensive patients on hemodi-
alysis should be very low. Then, these patients should be
monitored each 48 hours to evaluate the characteristics of
their BP profile.
Strict BP control in conjunction with antihypertensive
therapy, including ACE inhibitors, calcium channel block-
ers and beta blockers, may induce a regression of LVH [71].
However, the reduction of LVMI after the antihypertensive
therapy may not only be due to a better control of BP,
because some drugs (such as ACE inhibitors) can result a
decrease in angiotensin II levels, which has been shown to
have a proliferative effect on cardiac fibroblasts and myo-
cardiocytes, independently of the antihypertensive and
hemodynamic effects of this group of drugs [72, 73]. In this
sense, Cannella et al recently showed the beneficial effect
of lisinopril on decreasing the LVMI in ten normotensive
patients on hemodialysis [74]. However, more studies are
required to determine both the best target BP and the most
appropriate antihypertensive agents in hemodialysis pa-
tients.
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